New HIV prevention shot under Real-World scrutiny

NCT ID NCT07473778

Recruiting now Prevention Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Mar 23, 2026 · Last updated May 15, 2026 · Updated 6 times

Summary

This study follows 3,000 people in the US who choose lenacapavir (a long-acting injection) to prevent HIV. Researchers want to see how well participants stick with the treatment over a year. The goal is to understand how this new PrEP option works in everyday clinics, not just in controlled trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

AHF - Pensacola
RECRUITING

Pensacola, Florida, 32503, United States
Be Well Medical Center
RECRUITING

Berkley, Michigan, 48072, United States
Bliss Health
RECRUITING

Orlando, Florida, 32803, United States
Chase Brexton Health Care
RECRUITING

Baltimore, Maryland, 21201, United States
Faebris Medical & Community Education
RECRUITING

Atlanta, Georgia, 01111, United States
KC Care Health Center
RECRUITING

Kansas City, Missouri, 64111, United States
Mills Clinical Research
RECRUITING

West Hollywood, California, 90046, United States
Pacific Oaks Medical Group
RECRUITING

Beverly Hills, California, 90211, United States
Pineapple Healthcare Orlando
RECRUITING

Orlando, Florida, 32829, United States
The Aliveness Project
RECRUITING

Minneapolis, Minnesota, 55409, United States

Conditions

Explore the condition pages connected to this study.

HIV INFECTIONS